MetaADEDB 2.0 @ LMMD
besifloxacin
(PMQBICKXAAKXAY-HNCPQSOCSA-N)
Structure
SMILES
N[C@@H]1CCCCN(C1)c1c(F)cc2c(c1Cl)n(cc(c2=O)C(=O)O)C1CC1.Cl
Molecular Formula:
C19H22Cl2FN3O3
Molecular Weight:
430.301
Log P:
4.7120
Hydrogen Bond Acceptor:
6
Hydrogen Bond Donor:
3
TPSA:
88.56
CAS Number(s):
405165-61-9
Synonym(s)
1.
besifloxacin
2.
7-((3R)-aminohexahydro-1H-azepin-1-yl)-8-chloro-1-cyclopropyl-6-fluoro-1,4-dihydro-4-oxo-3-quinolinecarboxylic acid
3.
7-(3-aminohexahydro-1H-azepin-1-yl)-8-chloro-1-cyclopropyl-6-fluoro-1,4-dihydro-4-oxo-3-quinolinecarboxylic acid
4.
BOL-303224-A
5.
besifloxacin hydrochloride
6.
besivance
External Link(s)
MeSHC522124
PubChem Compound10224595
CHEMBLCHEMBL1201761
KEGGdr:D08872
Adverse Drug Event(s)
NameNumber of ReportsReference(s)Data Source
1Eye irritationFAERS: 19US FAERS
2Eye painFAERS: 14US FAERS
3Drug ineffectiveFAERS: 10US FAERS
4Product physical consistency issueFAERS: 8US FAERS
5Eye inflammationFAERS: 7US FAERS
6Corneal OpacityFAERS: 5US FAERS
7Foreign body sensation in eyesFAERS: 5US FAERS
8Inappropriate schedule of drug administrationFAERS: 5US FAERS
9Medication residue presentFAERS: 5US FAERS
10Product quality issueFAERS: 5US FAERS
11Toxicity to various agentsFAERS: 5US FAERS
12Eyelid margin crustingFAERS: 4US FAERS
13HeadacheFAERS: 4US FAERS
14No adverse eventFAERS: 3US FAERS
15Accidental exposure to productFAERS: 2US FAERS
16AstheniaFAERS: 2US FAERS
17Deposit eyeFAERS: 2US FAERS
18Drug dose omissionFAERS: 2US FAERS
19EndophthalmitisFAERS: 2US FAERS
20Eye InfectionFAERS: 2US FAERS
21Feeling jitteryFAERS: 2US FAERS
22HypopyonFAERS: 2US FAERS
23NauseaFAERS: 2US FAERS
24Ocular discomfortFAERS: 2US FAERS
25PainFAERS: 2US FAERS
26Product closure issueFAERS: 2US FAERS
27Product dropper issueFAERS: 2US FAERS
28AnxietyFAERS: 1US FAERS
29Application site erythemaFAERS: 1US FAERS
30Application site painFAERS: 1US FAERS
31Burning sensationFAERS: 1US FAERS
32Cataract operationFAERS: 1US FAERS
33Chest PainFAERS: 1US FAERS
34Cold sweatFAERS: 1US FAERS
35ConjunctivitisFAERS: 1US FAERS
36Corneal epithelium defectFAERS: 1US FAERS
37DizzinessFAERS: 1US FAERS
38Drug toxicityFAERS: 1US FAERS
39ErythemaFAERS: 1US FAERS
40Eye allergyFAERS: 1US FAERS
41Eye ulcerFAERS: 1US FAERS
42FatigueFAERS: 1US FAERS
43HypersensitivityFAERS: 1US FAERS
44Incision site inflammationFAERS: 1US FAERS
45Incorrect dose administeredFAERS: 1US FAERS
46Incorrect drug administration durationFAERS: 1US FAERS
47Intentional product use issueFAERS: 1US FAERS
48LagophthalmosFAERS: 1US FAERS
49Lip swellingFAERS: 1US FAERS
50MalaiseFAERS: 1US FAERS
51Medication residueFAERS: 1US FAERS
52PalpitationsFAERS: 1US FAERS
53PhlebitisFAERS: 1US FAERS
54PhotophobiaFAERS: 1US FAERS
55Post procedural complicationFAERS: 1US FAERS
56Product depositFAERS: 1US FAERS
57Product physical issueFAERS: 1US FAERS
58Product storage errorFAERS: 1US FAERS
59Product taste abnormalFAERS: 1US FAERS
60Product use in unapproved indicationFAERS: 1US FAERS
61PruritusFAERS: 1US FAERS
62Punctate keratitisFAERS: 1US FAERS
63Staphylococcus testFAERS: 1US FAERS
64SwellingFAERS: 1US FAERS
65SyncopeFAERS: 1US FAERS
66UrticariaFAERS: 1US FAERS
Powered by :

Page last updated at 2020-05-25 10:01:57 (Asia/Shanghai) | You are visitor No. 120239

Copyright © 2019-2020 Laboratory of Molecular Modeling and Design, Shanghai Key Laboratory of New Drug Design, School of Pharmacy, East China University of Science and Technology. All rights reserved.